Ruvim Izikson

Sanofi (United States) — United States

Medicine · Health Sciences

12h-index1.3kcitations26works2.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(21), Respiratory viral infections research(17), SARS-CoV-2 and COVID-19 Research(3), Pneumonia and Respiratory Infections(3), Vaccine Coverage and Hesitancy(3)

Publications26 total

P-2192. The Burden of Respiratory Syncytial Virus Among Young Children in the United States is Not Well-Documented Across Settings: A Systematic Literature Review
Open Forum Infectious Diseases·2026Open Access
564. Nirsevimab effectiveness in infants against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) and related healthcare utilization
Open Forum Infectious Diseases·2026Open Access
Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants
PEDIATRICS·2025· 9 citedOpen Access
Corrigendum to ‘Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants’ [AJOG Global Reports Volume 4, Issue 4, November 2024, 100395]
AJOG Global Reports·2025Open Access
P-717. Genetic Analysis of A(H3N2) Influenza Viruses and Associations with Host Characteristics among Kaiser Permanente Northern California Adults during the 2018-2019 Season
Open Forum Infectious Diseases·2025Open Access
Effectiveness of nirsevimab in infants against respiratory syncytial virus and related events
Annals of Allergy Asthma & Immunology·2024· 2 cited
Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants
AJOG Global Reports·2024· 4 citedOpen Access
Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study
Vaccine·2022· 4 citedOpen Access
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study
2021· 2 citedOpen Access
Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study
Open Forum Infectious Diseases·2020· 8 citedOpen Access
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial
PEDIATRICS·2018· 13 cited
Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans
mSphere·2017· 44 citedOpen Access
Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age
The Journal of Infectious Diseases·2017· 51 citedOpen Access
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
New England Journal of Medicine·2017· 274 cited
Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin
mBio·2017· 156 citedOpen Access
Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial
Vaccine·2017· 12 cited
Recombinant hemagglutinin influenza vaccine provides broader spectrum protection
Expert Review of Vaccines·2016· 28 cited
Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans
mBio·2016· 152 citedOpen Access
Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age
Vaccine·2015· 40 cited
Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults
Therapeutic Advances in Vaccines·2015· 134 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Manon Cox(11), Lisa M. Dunkle(10), P. Patriarca(8), Nicola P. Klein(7), Karen L. Goldenthal(6), John Hansen(6), Amber Hsiao(5), Ned Lewis(4), Derek Muse(3), John J. Treanor(3), Raffael Nachbagauer(3), Florian Krammer(3), Penny Post(3), Bruce Fireman(3), Julius Timbol(3), Ajinkya Inamdar(3), Heidi Kabler(3), Hana M. El Sahly(2), Robert Kohberger(2), Fatima Amanat(2)